Skip to main content

Table 4 In vivo animal study details

From: Development, optimization and pharmacokinetic evaluation of biphasic extended-release osmotic drug delivery system of trospium chloride for promising application in treatment of overactive bladder

Group

Number of samples

Time points (h)

Study days

Blood volume collected

Anticoagulant

Male

Female

Trospium chloride ER tablets 60 mg OROS tablets (test product)

03

00

0 h before administration and 1, 3, 5, 8, 10, 12, 14, 16, 18, 21, 24 h after administration

1 day

0.7 mL

K3 EDTA

Sanctura® XR capsules 60 mg (innovator CAPSULES) (reference product)

02

01

0 h before administration and 1, 3, 5, 8, 10, 12, 14, 16, 18, 21, 24 h after administration

1 day

0.7 mL

K3 EDTA